Adverum Biotechnologies ADVM

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.05 (-1.08%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Adverum Biotechnologies (ADVM)
    Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $4.58

    • Market Cap

      $95.28 Million

    • Price-Earnings Ratio

      -3.52

    • Total Outstanding Shares

      20.80 Million Shares

    • Total Employees

      121

    • Dividend

      No dividend

    • IPO Date

      July 31, 2014

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      100 cardinal way, Redwood city, CA, 94063

    • Homepage

      https://www.adverum.com

    Historical Stock Splits

    If you bought 10 shares of ADVM before March 21, 2024, you'd have 1 share today.
    Execution DateSplit Amount
    March 21, 20241-for-10 (Reverse Split)

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-21.12 Million
    Net Cash Flow From Investing Activities, Continuing$-13.35 Million
    Net Cash Flow From Operating Activities, Continuing$-21.12 Million
    Net Cash Flow From Financing Activities$0
    Net Cash Flow$-34.47 Million
    Net Cash Flow, Continuing$-34.47 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Basic Earnings Per Share$-1.30
    Preferred Stock Dividends And Other Adjustments$0
    Diluted Earnings Per Share$-1.30
    Research and Development$20.44 Million
    Net Income/Loss$-27.13 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$-26.88 Million
    Comprehensive Income/Loss Attributable To Parent$-26.88 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-26.88 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Liabilities$90.26 Million
    Accounts Payable$2.11 Million
    Current Liabilities$27.66 Million
    Cash$153.20 Million
    Liabilities And Equity$234.38 Million
    Fixed Assets$12.21 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ADVM from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.